EHA 2025 – Oncology Resource Group

Tina Shadpour, PharmD, MS

CONFERENCE LEAD ANALYST

["Hematologic Malignancies","Cell Therapies","ALL","MPNs","AML","MM","MDS","CLL","NHL","Immuno-Oncology: Late Stage","ADC"]

ONCrg Conference Coverage

Solid Tumors

MOAs

HEME

The European Hematology Association Congress includes significant clinical updates for hematological malignancies, often complementing ASCO with uniquely impactful presentations. The ONCrg team of experts is optimally positioned to contextualize data from EHA during the fast-paced June conference season.

Drawing on expertise honed year-round by our dedicated disease area specialists, ONCrg prepares detailed agendas identifying high-impact presentations. During and immediately after the conference, our team of experts sifts through the presentations, paying close attention to details while also placing them into the context of the clinical landscape at large. ONCrg’s unique conference reports provide clients with clear, digestible top-line trends backed by granular developments. Ask our Conference Lead Analyst about ONCrg Conference coverage.

Before the Conference:

A few weeks prior to each conference, our experts carefully examine all abstracts to identify presentations and posters most likely to relay new data with the potential to impact the marketplace. Clients are then invited to review our coverage plans, recommend additions, and indicate priorities for their organizations.

After the Conference:

With a cutting-edge understanding of competitive landscapes, we rigorously sift through presented data, comparing the information against past results to deliver incisive slide decks to clients rather than a lengthy collection of everything that was presented or rehash of old data. Following a conference, we deliver an executive-style PowerPoint report in a timely manner.

Before the Conference:

After the Conference:

Before the Conference:

During the Conference:

After the Conference:

Before the Conference:

During the Conference:

After the Conference:

“My team here loves the work ONCrg does – we are constantly pulling these reports up for various reasons and they are so AWESOME! Thanks so much!”

“Wow, very helpful and nice. I appreciate the preview of coming attractions! Thank you very much, helps my story a lot with this unbiased view of the market…”

“I have to say, this is one of the best intelligence services I have ever used. You and your team do a great job”

“What I value most from ONCrg is the unfiltered unbiased view you give irrespective of what manufacturers say. We love the key implications you put together and why they matter”

“As always you guys hit these reports out of the park!! These are so great…. for the first time I’m not making data slides post conferences so thank you for that!”

“ I really liked your past, present and future perspectives. This is some of the best work I have ever seen from a vendor.”

“BRAVO!! Most comprehensive map that I have reviewed for current SOC; and then every MoA and compound in development. Very Impressive. My hat is tipped to your team. I will distribute it across to my team and School is in Session.”

“Our organization is extremely frugal so we always have budget challenges but your value us extremely good and we love working with you so we absolutely want to continue investing in ONCrg.”

“These reports are incredibly informative and helpful as we think about our research strategy and drug developments options in these indications. I greatly appreciate you and the ONCrg team’s efforts to generate these reports and summaries.

“This is great! Until you’ve tried to attend a conference and make sense of what you saw and heard there, you can’t appreciate how hard it is to do it, so this is a really nice way of distilling the information.”

“I have been supporting myeloma brand for 3 years. This level of quality is what I am personally looking for and beyond what typical CI vendors can do….I see you have subject matter experts in each therapeutic area.”

“ONCrg has really good data and really good analysts, which was not what I found at Big Pharma or Small Pharma”

“I really appreciate working with you and the great support you have provided over the last couple of years! The internal feedback was quite positive: Very clear and precise statements; nice format – holistic and comprehensive”

“This is an outstanding summary of ASCO GU! We really appreciate all the detailed summaries and implications provided in this report. The clear insights your team provide continue to be fantastic! We use your upfront slides to convey complicated information to senior leadership.”

“Wow! This is amazing. Literally exactly what I was looking for. Thanks so much!! You’re the best.”

“This fully answers my question. This additional information and timely response is also extremely helpful in filling some of the gaps I had as I prepare for upcoming governance meetings.”

“My organization relies so heavily on ONCrg. I’m one of the strongest advocates and will continue to be, not just for conferences but across the board. “Our senior managers absolutely love the competitive landscape diagrams in your Pipeline Strategies reports.”

“I love the tumor specific reports that give me a lay of the land, are easily digestible. I really appreciate the implications and commentary in each report.”

“I know that many really like what you’re doing…everyone was thankful and found the reports very helpful”

I have always found the ONCrg reports to be valuable and to have evolved in sync with the changing times in oncology (not all vendors have).”

“The fact that ONCrg got our vaccine right is proof that we have done our research”. Also, there were 3 things I picked up from your vaccine presentation that I didn’t know. Quite helpful.”

“The way you do implications was exactly how I would like them to be delivered from a company covering them at ESMO”

“Thank you so much for the Onc-rg reports that your team provides. These reports are very helpful to the field medical team!”

“Thanks team, this is making my life easier already”

“I am quite impressed with the approach that you have taken to developing market assessments based on clinical trials reporting in a variety of settings. I appreciate the access to the meeting trials compendia in my core areas of interest”

“Thank you for the excellent work that you have delivered and for the wonderful partnership we have enjoyed.”

“I find the depth of information and their very succinct explanations to be extremely well written and easy to read, so this would enable me to stay aware of compounds moving up the ladder. Great work”

“I assume you have many clients, so I really appreciate how you can customize the coverage to our needs, I don’t know how you do it.”

“Take the opportunity to check out the “Implications” box on each slide. This agency is excellent at providing valuable context for new data. We will get these reports once a month as well as some really helpful supplementary reports.”

“Thanks for the support and fantastic customer service.”

“Thanks for all the ASCO updates in RCC, breast, IO, etc. They really are terrific and help tremendously with our MA debrief…”

Before the Conference:

During the Conference:

After the Conference:

Before the Conference:

During the Conference:

After the Conference:

Footer